Special communicationA multinational case-control study of cardiovascular disease and steroid hormone contraceptives: Description and validation of methods
References (23)
- et al.
Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies
Am J Obstet Gynecol
(1985) The WHO collaborative study of neoplasia and steroid contraceptives: the influence of combined oral contraceptives on risk of neoplasms in developing and developed countries
Contraception
(1991)- et al.
Prevalence and trends in oral contraceptive use in premenopausal females ages 12–54 years, USA, 1971–1980
Am J Public Health
(1985) Recent trends in contraceptive behaviour
The advance of the contraceptive revolution
World Health Stat Q
(1994)- Jordan WM. Pulmonary embolism. Lancet 2: 1146–1147...
Female hormones and vascular disease: an epidemiological overview
Br J Fam Planning
(1980)Oral contraceptives and cardiovascular disease, part 1
New Engl J Med
(1981)Oral contraceptives and cardiovascular disease, part 2
New Engl J Med
(1981)- et al.
Understanding US fertility: findings from the National Survey of Family Growth, Cycle III
Popul Bull
(1984)
Trends in use of oral contraceptives in Britain
Br J Fam Planning
Cited by (73)
Progestin-only contraception and thromboembolism: A systematic review
2016, ContraceptionCurrent issues and available options in combined hormonal contraception
2011, ContraceptionCitation Excerpt :The estrogen-associated increase in VTE appears to be proportional to degree of estrogen exposure and varies with the type of progestin used [55,56]. Surprisingly, third-generation progestins (DSG and GES), which are perceived as safer than other progestins, have been shown to have a twofold (range, 1.6–2.6) higher risk of idiopathic VTE compared with second-generation progestins (LNG and norethindrone) [54,84,85]. These results, however, have been questioned due to methodological bias and confounders in these studies, as other epidemiological studies did not find such a difference [84].
The Transnational study of oral contraceptive cardiovascular safety: history and science
2009, Journal of Clinical EpidemiologyCitation Excerpt :The Saskatchewan study was rejected because gestodene was not available in Saskatchewan, and other low-dose COCs, by themselves, were not relevant to the sponsors [6]. Initially called the Trinational study, because it was first conducted in Germany, the United Kingdom and France, it was decided that the study would benefit from emulating as closely as possible the methodology of the study conducted by the World Health Organisation (WHO)'s Human Reproduction Unit [7]. That study, international in nature, was already underway, and its emulation would facilitate comparisons and would allow an eventual combination of data.
Update on the progestin-only contraception
2009, Revue Sage - FemmeUpdate on the progestin-only contraception
2008, Journal de Gynecologie Obstetrique et Biologie de la ReproductionCentral Venous Sinus Thrombosis in a Young Woman Taking Norethindrone Acetate for Dysfunctional Uterine Bleeding: Case Report and Review of Literature
2008, Journal of Obstetrics and Gynaecology Canada
- ∗
Funded by: UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development, and Research Training in Human Reproduction and the National Institutes of Health Contraceptive and Reproductive Evaluation Branch [contract National Institutes of Child Health and Human Development (NICHD) NO1-HD-0-2914].
- †
Centres and principal investigators: Myriam Debert-Ribeiro, Departmento de Medicina Preventiva, Escola Paulista de Medicina, Sao Paulo, Brazil; Ernesto Medina, Escuela de Salud Publica, Universidad de Chile, Santiago, Chile; Jorge Artigas, Departmento de Salud Publica, Escuela de Medicina, Valparaiso, Chile; Shen He, National Research Institute for Family Planning, Beijing, China; Zhong Yu Hui, Sichuan Family Planning Research Institute, Chengdu, China; Zhang De-Wei, Shanghai Institute for Planned Parenthood Research, Shanghai, China; Oscar Rojas, Facultad de Salud, Universidad del Valle, Cali, Colombia; Martin Vessey, Department of Public Health and Primary Care, University of Oxford, Oxford, UK; Lothar Heinemann, Zentrum fur Epidemiologie and Gesundheitsforschung, Berlin, Germany; Stuart Donnan and Suzanne Ho, Department of Community Medicine, Chinese University of Hong Kong, Hong Kong; Gyorgy Bartfai, Department of Obstetrics and Gynaecology, University Medical School, Szeged, Hungary; J. Kisjanto, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Rainford Wilks, Tropical Metabolism Research Unit, University of the West Indies, Kingston, Jamaica; Reuben Agwanda, Kenya Medical Research Institute, Nairobi, Kenya; Rossario Ruiz, Grupo Interuniversitario Mexicano de Investigaçion Epidemiologica en Salud Reproductiva, Durango, Mexico; Mateja Kozuh-Novak, University Institute of Public Health, Ljubljana, Slovenia; Nikorn Dusitsin, Pramuan Virutamasen, and Kammant Phanthumchinda, Department of Obstetrics and Gynaecology, Chulalongkorn Hospital, Suporn Koetsawang, Siriraj Family Planning Research Center, Siriraj Hospital, Bangkok, Thailand; Jasenka Demirovic and Karen Belkic, School of Medicine, University of Belgrade, Belgrade, Federal Republic of Yugoslavia; W.S. Mwandila and C.M. Mutale, University Teaching Hospital, Lusaka, Zambia; and Jonathan Matenga and Adrian Wilson, Department of Medicine, University of Zimbabwe, Harare, Zimbabwe.
- §
Study and data coordination: N.R. Poulter (Study Coordinator and Co-Principal Investigator); C.L. Chang (Statistician and Data Manager); S. Lawley (Data Processor); M.G. Marmot (Co-Principal Investigator); S. Smith (Data Processor); Department of Epidemiology and Public Health, University College London Medical School, London, UK.
- ∥
Publications advisory committee: T.M.M. Farley, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development, and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland; J. Kelaghan, National Institutes of Health, Bethesda, MD, USA; M.G. Marmot, University College London Medical School, London, UK; O. Meirik, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland; J. Olsen, Danish Epidemiology Science Centre, University of Aarhus, Denmark; and M. Thorogood, London School of Hygiene and Tropical Medicine, London, UK.
- #
Manuscript prepared by: N.R. Poulter, C.L. Chang, T.M.M. Parley, and M.G. Marmot.